Reed Sarah Burgess 4
4 · Vor Biopharma Inc. · Filed Sep 10, 2025
Insider Transaction Report
Form 4
Reed Sarah Burgess
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-09-08+60,000→ 60,000 totalExercise: $1.98Exp: 2035-09-07→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on September 8, 2025, in each case subject to the Reporting Person's continued service as of each such date.
- [F2]Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.